iRhythm Holdings, Inc. (IRTC) iRhythm Technologies, Inc. is a digital healthcare enterprise dedicated to offering portable electrocardiogram (ECG) monitoring solutions to individuals in the United States who face the risk of cardiac arrhythmias. Its primary offering, the Zio service, provides a comprehensive ambulatory cardiac monitoring system. This system ingeniously combines a wireless, patch-based, and wearable biosensor—specifically embodied in products like the Zio XT and AT monitors—with a sophisticated cloud-based data analysis platform. These single-use biosensors precisely record a patient's heartbeats and ECG data, thereby enabling medical professionals to effectively oversee patient heart health and accurately diagnose arrhythmias. Furthermore, iRhythm maintains a strategic development partnership with Verily Life Sciences LLC, focused on pioneering future atrial fibrillation screening, detection, and monitoring innovations. Founded in 2006, the company maintains its corporate headquarters in San Francisco, California.
Sector: Surgical & Medical Instruments & Apparatus
Industry: Medical - Devices
iRhythm Technologies, Inc. NASDAQ:IRTC Healthcare · Medical - Devices
Mkt Cap $4.07B
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
iRhythm Holdings to Report Third Quarter 2026 Financial Results on November 5, 2026
iRhythm Holdings announced it will release Q3 2026 financial results after the close of trading on Thursday, November 5, 2026.
Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET, with a live and archived webcast available at investors.irhythmtech.com.
• 17d ago AI analysis › Press Release ● Major ⚠ 2
iRhythm Completes Acquisition of VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care
iRhythm completed its acquisition of VitalConnect, a wearable biosensor and ambulatory cardiac monitoring company, for $237.5 million in cash plus up to 423,334 shares, funded from the balance sheet.
The deal adds mobile cardiac telemetry and multi-vitals capabilities, including up to 30-day monitoring of up to 11 physiological parameters, extending iRhythm into inpatient and hospital-to-home settings.
Management expects the transaction to enhance revenue growth beginning in 2027 while preserving the previously communicated 15% adjusted EBITDA margin target; updated 2026 guidance including VitalConnect will come on the November 5 Q3 earnings call.
• 27d ago AI analysis › Press Release ⚠ 3
iRhythm Provides Update on Cybersecurity Incident Previously Disclosed in June 2026
iRhythm completed its forensic investigation of the June 2026 cybersecurity incident and began notifying impacted individuals on October 2, 2026.
Data accessed and downloaded by unauthorized individuals between June 3 and June 8, 2026 included patient names, contact information, account numbers, device serial numbers, insurance numbers, dates of service, and dates of birth.
The company says it has no evidence of identity theft, no impact to products or medical device systems, and reiterates the incident is not reasonably likely to be financially material.
• 0mo ago AI analysis › Press Release
iRhythm Holdings to Participate in Wells Fargo 21st Annual Healthcare Conference
iRhythm Holdings announced that its management will present at the Wells Fargo 21st Annual Healthcare Conference.
The fireside chat is scheduled for Wednesday, September 9, 2026, at 8:45 a.m. ET.
A live and archived webcast of the presentation will be accessible via the company's investor relations website.
• 2mo ago AI analysis › Press Release ● Major
iRhythm to Acquire VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care
iRhythm Holdings has agreed to acquire privately held VitalConnect for approximately $287.5 million to expand its cardiac monitoring platform across ambulatory, inpatient, and hospital-to-home care settings.
The deal combines iRhythm’s existing Zio service with VitalConnect’s mobile cardiac telemetry and multi-vitals monitoring capabilities, broadening the company's addressable market and patient care pathways.
Management expects the transaction to be accretive to revenue growth beginning in 2027 while maintaining the previously communicated 15% adjusted EBITDA margin target.
• 2mo ago AI analysis › Press Release ● Major ⚠ 2
iRhythm Holdings Announces Second Quarter 2026 Financial Results
iRhythm reported Q2 2026 revenue of $224.2 million, up 20.1% year-over-year, with gross margin expanding 160 basis points to 72.8% and net loss narrowing significantly to $0.4 million.
The company raised its full-year 2026 revenue guidance to $880 million-$890 million and adjusted EBITDA margin guidance to 13.0%-14.0%, citing volume-led growth and operating leverage.
Additionally, iRhythm entered a definitive agreement to acquire VitalConnect for approximately $287.5 million and achieved FDA clearance for its third-generation algorithm.
• 2mo ago AI analysis › Press Release
iRhythm Holdings to Report Second Quarter 2026 Financial Results on August 6, 2026
iRhythm Holdings announced that it will report its second quarter 2026 financial results after the market closes on Thursday, August 6, 2026.
Management will host a conference call to discuss the results at 1:30 p.m. PT / 4:30 p.m. ET on the same day.
Investors can access a live and archived webcast of the call via the company's investor relations website.
• 3mo ago AI analysis › Press Release ⚠ 3
16 Million People, One Underserved Disease: The AI Imaging Push to Close the Congenital Heart Gap
This paid advertisement highlights Ventripoint Diagnostics' support for the Global Congenital Heart Disease Alliance, including the placement of four VMS+ imaging units.
The article contextualizes congenital heart disease as a growing market opportunity, citing 16 million affected patients and a projected AI cardiology market growing to $14.2 billion by the 2030s.
Butterfly Network (BFLY) is mentioned solely as a competitive proxy in the point-of-care ultrasound space; the release is not an issuer disclosure from BFLY.
• 4mo ago AI analysis › Press Release
iRhythm Holdings to Participate in Upcoming Investor Conferences
globenewswire.com • 5mo ago Press Release ● Major
iRhythm Holdings Announces First Quarter 2026 Financial Results
globenewswire.com • 6mo ago Press Release
iRhythm Holdings to Present at the Bank of America Securities 2026 Health Care Conference
iRhythm Holdings announced that management will participate in the upcoming Bank of America Securities 2026 Health Care Conference.
The presentation is scheduled for Wednesday, May 13, 2026, at 12:20 p.m. Eastern Time.
A live and archived webcast will be available on the Events & Presentations section of the company's investor website.
• 6mo ago AI analysis › Press Release
New Data Presented at HRS 2026 Show Short-Term Holter Monitoring Misses a Large Proportion of AF Recurrence Post-Ablation and Clinically Significant Arrhythmias in Pregnancy
globenewswire.com • 6mo ago Press Release ● Major
iRhythm Holdings to Report First Quarter 2026 Financial Results on April 30, 2026
globenewswire.com • 6mo ago Press Release
Data presented at ACC.26 further demonstrate the benefits of iRhythm's Zio® ambulatory ECG portfolio across multiple patient populations as company launches new digital education platform
globenewswire.com • 7mo ago Press Release ● Major
iRhythm Holdings Appoints Jason Patten to its Board of Directors
globenewswire.com • 7mo ago Press Release ● Major
iRhythm Holdings Announces Fourth Quarter and Full Year 2025 Financial Results
globenewswire.com • 8mo ago Press Release ● Major
iRhythm Holdings to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
globenewswire.com • 8mo ago 
